Abiomed's success story began in Aachen - the “Birthplace of Heart Recovery”. This is where the Impella® heart pump was invented in the early 1990s and has been continuously developed ever since. In addition to local production, Aachen marks the starting point for the worldwide distribution of our technologies, which have now been benefiting patients all over the world for over 25 years.

A New Chapter Begins With Johnson & Johnson MedTech

From the beginning, our vision has been clear: to make heart recovery the global standard of care. Our mission aligns with this goal by striving to recover as many hearts as possible with the Impella® heart pump, always placing patients at the center of our thoughts and actions — "Patients First."

In 2022, a new chapter in our history began when the world's largest medical technology company, Johnson & Johnson (J&J), acquired Abiomed as part of its portfolio. This partnership reflects the shared values of Abiomed and J&J, bringing us one step closer to realizing our vision of recovering hearts and establishing the Impella therapy as the global standard of care. Our mission and vision, therefore, remain unchanged and are embraced by J&J.

With the support of Johnson & Johnson, we have the opportunity to accelerate the realization of our vision. By 2024, we expect that 60,000 patients will be treated with the Impella® heart pump — a record number, and a one-third increase compared to the period prior to J&J's acquisition. Encouraged by this success, J&J intends to further expand the heart recovery segment. The business unit “J&J MedTech | Heart Recovery” will be established globally. The Impella® brand will continue to represent our heart pump product category and all product-specific topics. The “Abiomed” brand will also be retained and will primarily be used for services related to the products, such as training platforms and software solutions.

What Does This Mean for You?

With the partnership through Johnson & Johnson MedTech, the brand identity of Abiomed will be different from January 2025 and will visually adapt to the brand identity of Johnson & Johnson MedTech. However, the content that is available to you across our communication channels will remain the same - same content, new design.

Please note that this change to our corporate identity does not impact our products and services or the way we collaborate with you. The change involves a merger of brands, not businesses. Therefore, the business responsibility for Abiomed remains with Abiomed Europe GmbH. The names of our products will remain unchanged, as will your contact persons.

Do you have any questions?Get in touch with your sales representative any time.